Affinia Therapeutics

Affinia Therapeutics’ AFTX-201 Earns FDA Fast Track Designation for BAG3-Associated Dilated Cardiomyopathy

Affinia Therapeutics Granted FDA Fast Track Designation for AFTX-201 as a Treatment for People Living with BAG3-Associated Dilated Cardiomyopathy (DCM) Affinia Therapeutics an innovative gene therapy company with a pipeline of first-in-class and/or best-in-class adeno-associated virus (AAV) gene therapies initially…

Read MoreAffinia Therapeutics’ AFTX-201 Earns FDA Fast Track Designation for BAG3-Associated Dilated Cardiomyopathy
HeartBeam

HeartBeam Secures First Commercial Customer as ClearCardio Adopts 12-Lead ECG Technology

HeartBeam Announces First Commercial Customer as ClearCardio Brings Groundbreaking 12-Lead ECG Technology to High-Growth Preventive Cardiology Market HeartBeam, Inc. a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, announced a commercial partnership with ClearCardio™, a leading preventive…

Read MoreHeartBeam Secures First Commercial Customer as ClearCardio Adopts 12-Lead ECG Technology
Pulse Biosciences

Pulse Biosciences’ nPulse Vybrance System to Be Highlighted at North American Society for Interventional Thyroidology Meeting

Pulse Biosciences’ nPulse™ Vybrance™ System to be Featured in Multiple Presentations at the North American Society for Interventional Thyroidology Meeting Pulse Biosciences, Inc. developer of the novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™)…

Read MorePulse Biosciences’ nPulse Vybrance System to Be Highlighted at North American Society for Interventional Thyroidology Meeting
Stevanato

Stevanato Group Reports 7% Revenue Growth in FY2025 with Record High-Value Solutions Revenue

Stevanato Group Delivers 7% Revenue Growth (9% at Constant Currency) for Fiscal Year 2025, Including Record Revenue from High-Value Solutions and Expanded Margins Stevanato Group S.p.A. a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical,…

Read MoreStevanato Group Reports 7% Revenue Growth in FY2025 with Record High-Value Solutions Revenue
Seaport

Seaport, Monash Awarded Up to $15M ARPA-H Grant for GlyphCele™

Seaport Therapeutics and Monash Institute of Pharmaceutical Sciences Awarded up to $15 Million from ARPA‑H to Advance Seaport’s GlyphCele™, the First Oral Therapeutic Designed to Restore Gut Lymphatic Function Seaport Therapeutics a clinical-stage therapeutics company advancing novel neuropsychiatric medicines with a…

Read MoreSeaport, Monash Awarded Up to $15M ARPA-H Grant for GlyphCele™
Lucidis

Lucidis® Elevates Premium Cataract Surgery with Exceptional Full-Range Vision Performance

Lucidis® Sets High Standards in Premium Cataract Surgery with Full-Range Vision Performance Swiss Advanced Vision announces new clinical evidence confirming the exceptional performance of its Lucidis® intraocular lens (IOL), strengthening its position as a disruptive solution in premium cataract surgery.…

Read MoreLucidis® Elevates Premium Cataract Surgery with Exceptional Full-Range Vision Performance
Syntis Bio

Syntis Bio Initiates Phase 1/1b Clinical Study of SYNT-101 in Obesity with First Patient Dosed

Syntis Bio Announces First Patient Dosed in Phase 1/1b Clinical Trial of SYNT-101 in Obesity and Key Leadership Additions Syntis Bio, Inc. a clinical-stage biopharmaceutical company advancing novel oral therapeutics that uniquely leverage the small intestine, today announced that the…

Read MoreSyntis Bio Initiates Phase 1/1b Clinical Study of SYNT-101 in Obesity with First Patient Dosed
Polares Medical

Polares Medical Boosts U.S. Expansion Plans with $50 Million Series C Following Encouraging Clinical Results

Polares Medical Raises $50 Million Series C to Advance U.S. Expansion of MRace Following Strong Clinical Results Polares Medical SA a clinical-stage structural heart company developing the MRace Posterior Leaflet Replacement (PLR) system for mitral regurgitation (MR), today announced the closing of…

Read MorePolares Medical Boosts U.S. Expansion Plans with $50 Million Series C Following Encouraging Clinical Results
Mobile

Mobile Heartbeat’s Banyan Platform Integrates with Microsoft Teams to Connect Health System Staff Enterprise-Wide

Mobile Heartbeat’s Banyan Platform Connects Health System Staff Across the Enterprise Through Microsoft Teams Mobile Heartbeat, a proven leader in enterprise clinical communication and collaboration (CC&C), is spotlighting how its Banyan platform’s Microsoft Teams integration is helping healthcare organizations extend secure, real-time…

Read MoreMobile Heartbeat’s Banyan Platform Integrates with Microsoft Teams to Connect Health System Staff Enterprise-Wide
Humana

Humana Launches New Value-Based Cardiology Care Partnerships for Medicare Advantage Members

Humana Introduces New Value-Based Cardiology Care Partnerships for Medicare Advantage Members Humana Inc. a leading U.S. healthcare company, today announced new partnerships to improve heart health for eligible Medicare Advantage members through value-based care. Building on Humana’s existing cardiac care partnership…

Read MoreHumana Launches New Value-Based Cardiology Care Partnerships for Medicare Advantage Members